IBC

Integrated BioTherapeutics (IBT) is a biotechnology company focused on the discovery and development of vaccines and antibody-based therapies for emerging infectious diseases and antibiotic-resistant bacteria. The company operates two primary divisions: IBT Vaccines, which develops proprietary pipeline candidates like the multivalent Staphylococcus aureus vaccine IBT-V02, and IBT Bioservices, a contract research organization (CRO) providing specialized infectious disease services to global pharmaceutical and government clients. IBT is a recognized leader in the field of bacterial toxins and viral pathogens, leveraging deep expertise in protein engineering and immunology to address high-priority biodefense and public health threats. Their portfolio includes advanced programs for S. aureus, Ebola, Marburg, and Anthrax, often supported by significant funding from the NIH and BARDA.